Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) SVP Laurie Keating sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 13th. The shares were sold at an average price of $145.00, for a total value of $2,900,000.00. Following the completion of the transaction, the senior vice president now directly owns 24,500 shares in the company, valued at $3,552,500. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Laurie Keating also recently made the following trade(s):
- On Tuesday, March 20th, Laurie Keating sold 1,562 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $149.83, for a total value of $234,034.46.
- On Wednesday, December 20th, Laurie Keating sold 6,249 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $121.20, for a total value of $757,378.80.
Shares of Alnylam Pharmaceuticals stock opened at $95.08 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 12.23 and a current ratio of 12.23. Alnylam Pharmaceuticals, Inc. has a 12 month low of $47.16 and a 12 month high of $153.99.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported ($1.48) EPS for the quarter, missing the consensus estimate of ($1.38) by ($0.10). Alnylam Pharmaceuticals had a negative net margin of 545.95% and a negative return on equity of 41.08%. The firm had revenue of $37.90 million for the quarter, compared to the consensus estimate of $19.31 million. During the same quarter last year, the company posted ($1.32) earnings per share. Alnylam Pharmaceuticals’s revenue for the quarter was up 116.6% compared to the same quarter last year. equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -7.02 earnings per share for the current year.
ALNY has been the subject of a number of recent analyst reports. BidaskClub upgraded Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, March 14th. Credit Suisse Group upped their price target on Alnylam Pharmaceuticals from $151.00 to $154.00 and gave the company an “outperform” rating in a research report on Tuesday, March 13th. B. Riley reaffirmed a “buy” rating and set a $205.00 price target (down previously from $220.00) on shares of Alnylam Pharmaceuticals in a research report on Monday, January 8th. Jefferies Group set a $156.00 price objective on Alnylam Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, February 9th. Finally, Leerink Swann increased their price objective on Alnylam Pharmaceuticals from $132.00 to $135.00 and gave the stock a “market perform” rating in a report on Thursday, January 25th. Four analysts have rated the stock with a sell rating, four have given a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $134.15.
A number of institutional investors and hedge funds have recently bought and sold shares of ALNY. Strs Ohio purchased a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at approximately $141,000. CENTRAL TRUST Co lifted its stake in shares of Alnylam Pharmaceuticals by 746.3% in the 4th quarter. CENTRAL TRUST Co now owns 1,134 shares of the biopharmaceutical company’s stock valued at $144,000 after purchasing an additional 1,000 shares during the period. Livforsakringsbolaget Skandia Omsesidigt purchased a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at approximately $165,000. The Manufacturers Life Insurance Company lifted its stake in shares of Alnylam Pharmaceuticals by 7.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock valued at $203,000 after purchasing an additional 167 shares during the period. Finally, Segall Bryant & Hamill LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at approximately $235,000. Institutional investors and hedge funds own 92.28% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/07/alnylam-pharmaceuticals-inc-alny-svp-laurie-keating-sells-20000-shares-of-stock.html.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.